Quarterly ResultJul 31, 2026, 04:13 PM
FibroBiologics Reports Going Concern Doubt, $3.5M Cash
AI Summary
FibroBiologics, Inc. reported a net loss of $4.1 million for Q2 2026, an improvement from $4.7 million in Q2 2025, and a net loss of $9.1 million for the six months ended June 30, 2026. Despite the reduced losses, the company's cash and cash equivalents decreased to $3.5 million as of June 30, 2026, from $4.9 million at year-end 2025. Management has raised substantial doubt about the company's ability to continue as a going concern due to ongoing operating losses and reliance on additional capital.
Key Highlights
- Management raised substantial doubt about the company's ability to continue as a going concern.
- Net loss for Q2 2026 was $4.1 million, an improvement from $4.7 million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.66), compared to $(2.41) in Q2 2025.
- Cash and cash equivalents totaled $3.5 million as of June 30, 2026, down from $4.9 million at December 31, 2025.
- Accumulated deficit increased to $63.3 million as of June 30, 2026.
- Net cash used in operating activities for H1 2026 was $7.7 million, an improvement from $9.3 million in H1 2025.
- Total operating expenses for Q2 2026 decreased to $4.0 million from $4.5 million in Q2 2025.
Price Impact
More from FBLG